Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Botanix PharmaceuticalsASX:BOT -5.00% EV-to-EBIT is -0.59 as of Aug. 01, 2026. The stock has 7 warning signs investors should review. Among 382 Biotechnology companies, Botanix Pharmaceuticals ranks worse than 261779.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Botanix Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was A$264.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-85.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Botanix Pharmaceuticals EV-to-EBIT Related Terms
Botanix Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BOT vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Botanix Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Botanix Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Botanix Pharmaceuticals's EV-to-EBIT falls into.
Botanix Pharmaceuticals's current Enterprise Value is A$50.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Botanix Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-85.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Botanix Pharmaceuticals (ASX:BOT) has a EV-to-EBIT of -0.59 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Botanix Pharmaceuticals and its competitors. According to the industry distribution chart, Botanix Pharmaceuticals ranks #999999 out of 382 companies in the Biotechnology industry.
Is Botanix Pharmaceuticals' EV-to-EBIT too high?
Botanix Pharmaceuticals' current EV-to-EBIT is -0.59. Based on the distribution chart, Botanix Pharmaceuticals ranks #999999 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Botanix Pharmaceuticals' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #999999 out of 382 companies for EV-to-EBIT. This places Botanix Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Botanix Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Botanix Pharmaceuticals's current EV-to-EBIT is -0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (ASX:BOT) has a current EV-to-EBIT of -0.59. The current EV-to-EBIT is -0.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Botanix Pharmaceuticals (ASX:BOT), the current EV-to-EBIT is -0.59 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOT has been successfully added to your 
